HOUSTON--(BUSINESS WIRE)--Qbtech, the global leader in objective ADHD testing, today announced its one millionth patient milestone, amassing one of the most extensive data sets of patients tested for ADHD. Adopted by more than 12,000 healthcare providers worldwide, including 44 U.S. states, the company’s industry-leading tests provide evidence-based data for unbiased decision-making and enhanced patient care. Qbtech’s objective ADHD tools, QbTest and QbCheck, are FDA-cleared solutions for ADHD diagnostic and treatment support in children, adolescents and adults.
Transforming ADHD care through its technology-first approach, Qbtech’s objective ADHD tests seamlessly integrate into clinical pathways to facilitate a comprehensive diagnosis and more accurately and efficiently determine treatment effects. Dr. Nerissa S. Bauer, CEO of Let’s Talk Kids Health, LLC and creator of TEACH Me ADHD, uses Qbtech’s test in her practice and shared, “having QbTest as an additional tool helps round out the picture and gives clinicians and patients the data they need to feel more confident and comfortable.”
Available in-clinic and via telehealth, Qbtech’s devices measure motor activity down to the millimeter and aid in evaluating the core symptoms of ADHD – hyperactivity, inattention, and impulsivity – through a 15-20-minute computer-based test. Results are instantly presented in a report that compares a patient's results with an age and sex-at-birth-matched control group without ADHD. The highly visual representation of symptoms, shown as graphs and images on the reports, helps patients see their symptoms clearly, bringing transparency into the diagnostic and treatment management process.
“Given the complexities of ADHD, solely relying on opinion-based subjective data is not adequate for a comprehensive diagnosis,” said Dr. Mikkel Hansen, ADHD researcher and Medical Director at Qbtech. “Our technology is backed by more than two decades of expertise and delivers the highest-quality objective tests and processes in ADHD care. We bring clarity to a complex and dubious diagnostic process to meet the needs of patients while also adding necessary safeguards to ADHD treatment monitoring. We’re incredibly proud of reaching this significant milestone and look forward to supporting the tens of millions of patients seeking a diagnosis worldwide.”
Since its launch in Sweden in 2002, Qbtech has expanded globally. More than 40 independent studies document the company’s benefits across the patient care pathway, including improved access to care, elevated clinician confidence, a 50% better indication of treatment effects than self-rating, and standardization of care across multiple disciplines.
Visit www.qbtech.com to learn more.
About Qbtech
Founded in 2002, Qbtech is a privately-owned Swedish company that has developed leading solutions and products for improving the identification, diagnosis, treatment, and follow-up of patients living with ADHD. Qbtech has operations in 13 countries and has offices in Stockholm, Houston, and London. Qbtech is an award-winning company recognized for its innovation, most recently winning the 2022 HSJ Partnership Award for the ‘Best Mental Health Partnership with the NHS.’ For more information about Qbtech, visit www.qbtech.com.
